SHARE NOW
Thermo Fisher Scientific Inc., the world leader in serving science, and the University of California, San Francisco (UCSF), will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility next to UCSF Medical Center’s Mission Bay campus.
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies. Thermo Fisher can advantageously provide integrated solutions to cell therapy clients through high quality materials, services and support that accelerate workflow from discovery to clinical research and commercial manufacturing.
The partnership between Thermo Fisher and UCSF, first announced in 2021, has the potential to expedite the development of breakthrough treatments by having scientists, clinicians, and patients closer to a manufacturing site.
“With a record number of cell therapy approvals granted in the last two years, and CAR-T therapies becoming earlier treatment options, we’re in a golden age of biology, where new technologies and partnerships are evolving and transforming clinical care,” comments Michel Lagarde, Executive Vice President and CEO of Thermo Fisher.
How are you enjoying this news article? Let us know your thoughts, here >>
Thermo Fisher offers UCSF and other customers process and analytical development capabilities, as well as clinical and commercial manufacturing services, for advanced therapies derived from either a patient’s cells or from a donor source. Customers can also benefit from Thermo Fisher’s drug development capabilities from discovery to clinical research to commercialization.
“UCSF is one of the top clinical sites for CAR-T treatment, and our scientists are leading the next-generation of CAR-T therapy development,” said UCSF Chancellor Sam Hawgood, MBBS. “These approaches will be tested soon in patients with solid tumors like glioblastoma and later in other diseases, including autoimmunity.”
UCSF’s main focus at the facility will be on treatments for glioblastoma, multiple myeloma, and other cancers using updated approaches to CAR-T and CRISPR technologies. With therapies for other difficult to treat conditions to follow.
Source: Thermo Fisher Scientific Inc. Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
Discover more like this
